Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.

Kollessery G, Nordgren TM, Mittal AK, Joshi SS, Sanderson SD.

Vaccine. 2011 Aug 11;29(35):5904-10. doi: 10.1016/j.vaccine.2011.06.070. Epub 2011 Jul 1.

PMID:
21723901
2.

Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant.

Ulrich JT, Cieplak W, Paczkowski NJ, Taylor SM, Sanderson SD.

J Immunol. 2000 May 15;164(10):5492-8.

3.

A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells.

Hegde GV, Meyers-Clark E, Joshi SS, Sanderson SD.

Int Immunopharmacol. 2008 Jun;8(6):819-27. doi: 10.1016/j.intimp.2008.01.031. Epub 2008 Mar 3.

PMID:
18442785
5.

CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.

Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM.

J Immunol. 2004 Apr 1;172(7):4215-24.

6.

Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.

Armstrong AC, Dermime S, Allinson CG, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, Hawkins RE.

J Immunol. 2002 Apr 15;168(8):3983-91.

7.

Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.

Siegel S, Wagner A, Schmitz N, Zeis M.

Br J Haematol. 2003 Sep;122(6):911-4.

PMID:
12956760
8.

Development of a cancer vaccine: peptides, proteins, and DNA.

Shiku H, Wang L, Ikuta Y, Okugawa T, Schmitt M, Gu X, Akiyoshi K, Sunamoto J, Nakamura H.

Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82.

PMID:
10950153
10.

Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.

Gatza E, Okada CY.

J Immunol. 2002 Nov 1;169(9):5227-35. Erratum in: J Immunol. 2003 May 15;170(10):following 5332.

11.

Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.

Lu J, Higashimoto Y, Appella E, Celis E.

J Immunol. 2004 Apr 1;172(7):4575-82.

12.

Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma.

Curti A, Parenza M, Colombo MP.

Blood. 2003 Jan 15;101(2):568-75. Epub 2002 Aug 22.

13.

Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.

Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A, Darcy PK, Ramsay RG.

Cancer Immunol Immunother. 2008 Nov;57(11):1635-45. doi: 10.1007/s00262-008-0497-2. Epub 2008 Apr 3.

PMID:
18386000
14.

4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.

Guinn BA, DeBenedette MA, Watts TH, Berinstein NL.

J Immunol. 1999 Apr 15;162(8):5003-10.

15.

Anti-lymphoma immunity: relative efficacy of peptide and recombinant DNA vaccine.

Lim SY, Laxmanan S, Stuart G, Ghosh SK.

Cancer Detect Prev. 2001;25(5):470-8.

PMID:
11718453
16.
17.
18.

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.

Ilkovitch D, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. Epub 2004 Jan 17.

PMID:
14730400
19.

Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin.

Tempero RM, Hollingsworth MA, Burdick MD, Finch AM, Taylor SM, Vogen SM, Morgan EL, Sanderson SD.

J Immunol. 1997 Feb 1;158(3):1377-82.

PMID:
9013982

Supplemental Content

Support Center